PH12012501052A1 - Novel spiropiperidine compounds - Google Patents

Novel spiropiperidine compounds

Info

Publication number
PH12012501052A1
PH12012501052A1 PH1/2012/501052A PH12012501052A PH12012501052A1 PH 12012501052 A1 PH12012501052 A1 PH 12012501052A1 PH 12012501052 A PH12012501052 A PH 12012501052A PH 12012501052 A1 PH12012501052 A1 PH 12012501052A1
Authority
PH
Philippines
Prior art keywords
spiropiperidine compounds
novel spiropiperidine
novel
compounds
compound
Prior art date
Application number
PH1/2012/501052A
Other languages
English (en)
Inventor
Jayana Pankaj Lineswala
Pranab Maiti
Chafiq Hamdouchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012501052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH12012501052A1 publication Critical patent/PH12012501052A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4747Quinolines; Isoquinolines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH1/2012/501052A 2009-11-30 2010-11-19 Novel spiropiperidine compounds PH12012501052A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26518109P 2009-11-30 2009-11-30
PCT/US2010/057359 WO2011066183A1 (en) 2009-11-30 2010-11-19 Novel spiropiperidine compounds

Publications (1)

Publication Number Publication Date
PH12012501052A1 true PH12012501052A1 (en) 2013-02-04

Family

ID=43384775

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/501052A PH12012501052A1 (en) 2009-11-30 2010-11-19 Novel spiropiperidine compounds

Country Status (26)

Country Link
US (1) US8822486B2 (https=)
EP (1) EP2507228B1 (https=)
JP (1) JP5709889B2 (https=)
KR (1) KR101410103B1 (https=)
CN (1) CN102648195B (https=)
AR (1) AR078948A1 (https=)
AU (1) AU2010324987B2 (https=)
BR (1) BR112012012903A2 (https=)
CA (1) CA2781292C (https=)
CL (1) CL2012001321A1 (https=)
CR (1) CR20120296A (https=)
DO (1) DOP2012000139A (https=)
EA (1) EA020507B1 (https=)
EC (1) ECSP12011930A (https=)
ES (1) ES2526568T3 (https=)
GT (1) GT201200164A (https=)
IL (1) IL219594A0 (https=)
MA (1) MA33840B1 (https=)
MX (1) MX2012006233A (https=)
NZ (1) NZ600203A (https=)
PE (1) PE20121474A1 (https=)
PH (1) PH12012501052A1 (https=)
TN (1) TN2012000248A1 (https=)
TW (1) TW201141866A (https=)
WO (1) WO2011066183A1 (https=)
ZA (1) ZA201203055B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
CN104710381A (zh) 2009-12-25 2015-06-17 持田制药株式会社 新的3-羟基-5-芳基异噻唑衍生物
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
RU2013152631A (ru) 2011-04-27 2015-06-10 Мотида Фармасьютикал Ко., Лтд. Новое 3-гидроксиизотиазол-1-окидное производное
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
EP2970161B8 (en) * 2013-03-14 2018-10-17 Janssen Pharmaceutica NV Gpr120 agonists for the treatment of type ii diabetes
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
CN1768041A (zh) * 2003-04-04 2006-05-03 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
EP1795527B1 (en) * 2004-09-07 2009-04-22 Banyu Pharmaceutical Co., Ltd. Carbamoyl-substituted spiro derivative
CA2657639A1 (en) * 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
ATE486877T1 (de) * 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
AU2008241490B2 (en) * 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
BRPI0818687A2 (pt) * 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Also Published As

Publication number Publication date
TW201141866A (en) 2011-12-01
TN2012000248A1 (en) 2013-12-12
US8822486B2 (en) 2014-09-02
BR112012012903A2 (pt) 2017-03-01
CL2012001321A1 (es) 2013-11-15
ECSP12011930A (es) 2012-07-31
ES2526568T3 (es) 2015-01-13
AU2010324987B2 (en) 2014-01-30
CN102648195A (zh) 2012-08-22
PE20121474A1 (es) 2012-11-05
EA201290416A1 (ru) 2012-11-30
KR101410103B1 (ko) 2014-06-25
US20120220616A1 (en) 2012-08-30
WO2011066183A1 (en) 2011-06-03
ZA201203055B (en) 2013-09-25
MX2012006233A (es) 2012-07-03
KR20120088770A (ko) 2012-08-08
IL219594A0 (en) 2012-06-28
JP5709889B2 (ja) 2015-04-30
GT201200164A (es) 2014-02-27
CA2781292A1 (en) 2011-06-03
DOP2012000139A (es) 2012-08-15
MA33840B1 (fr) 2012-12-03
EP2507228B1 (en) 2014-11-05
CA2781292C (en) 2014-04-22
EA020507B1 (ru) 2014-11-28
EP2507228A1 (en) 2012-10-10
CN102648195B (zh) 2015-01-07
AR078948A1 (es) 2011-12-14
NZ600203A (en) 2013-09-27
AU2010324987A1 (en) 2012-07-26
CR20120296A (es) 2012-07-16
JP2013512277A (ja) 2013-04-11

Similar Documents

Publication Publication Date Title
TN2012000248A1 (en) Novel spiropiperidine compounds
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
SG178952A1 (en) Chemical compounds
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
WO2010108074A3 (en) Inhibitors of pi3 kinase
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
TN2013000434A1 (en) Novel imidazole derivatives useful for the treatment of arthritis
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
MY160392A (en) Triptolide prodrugs
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
MX2011008289A (es) Tabletas para terapia combinada.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
JO2979B1 (en) Cyclopropyl compounds
WO2012164055A3 (en) New compounds, synthesis and use thereof in the treatment of pain
NZ589911A (en) Styrylbenzofuran derivatives as inhibitors for beta-amyloid fibril formation and preparation method thereof
WO2012008765A3 (ko) 암 치료 또는 예방용 약학 조성물
TN2010000397A1 (en) Heterocyclic compounds
UA87608C2 (uk) Спосіб отримання ціанометилпіримідинів
UA60840U (ru) Способ лечения больных сахарным диабетом
TN2010000353A1 (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
JO2775B1 (en) 3-indazolil 4-pyridyl isothiazole